The Growth Dynamics of the Alprolix Market in Hemophilia B Treatment Introduction
Alprolix, recombinant factor IX therapy, a significant player in the treatment of haemophilia B--a rare but severe genetic disorder. Alprolix is doing well in the market, with strong growth. In addition to the popularity of hemophilia, it is benefiting from biopharmaceutical technology which has advanced to long-acting therapeutic options (LAOTs), and there are patients who require...
0 Geteilt
33 Ansichten
0 Bewertungen